ASH 2020 | CRB-402 study update: T-cell phenotypes in myeloma
Jesús Berdeja
• 11 Dec 2020
Jesús Berdeja, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the updated results from CRB-402 (NCT03274219), a Phase I study aiming to evaluate the efficacy and safety of bb21217, an anti-BCMA CAR-T product, in patients with relapsed/refractory multiple myeloma. While similar to ide-cel, this product allows for selection of memory phenotype T-cells, which may improve the duration of response. This line of therapy yielded encouraging response rates and was found to have an acceptable safety profile, with few toxicities being reported. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
